J. Dębniak

发表

Mutational analysis of BRCA1/2 in a group of 134 consecutive ovarian cancer patients. Novel and recurrent BRCA1/2 alterations detected by next generation sequencing

Å. Borg, M. Stukan, J. Limon, 2014, Journal of Applied Genetics.

Spectrum and Prevalence of Pathogenic Variants in Ovarian Cancer Susceptibility Genes in a Group of 333 Patients

M. Stukan, P. Kozłowski, J. Limon, 2018, Cancers.

High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland.

M. Stukan, J. Limon, M. Ratajska, 2008, Gynecologic oncology.

Cytogenetics of uterine sarcomas: presentation of eight new cases and review of the literature.

C. Bloomfield, K. Mrózek, N. Mandahl, 1998, Gynecologic oncology.

Prevalence and clinical correlations of BRCA1/BRCA2 unclassified variant carriers among unselected primary ovarian cancer cases - preliminary report.

P. Devilee, J. Jassem, C. Cornelisse, 2005, European journal of cancer.

Loss of heterozygosity atBRCA1/2 loci in hereditary and sporadic ovarian cancers

M. Stukan, J. Limon, M. Ratajska, 2010, Journal of Applied Genetics.

Sertoli cell tumor in androgen insensitivity syndrome--a case report.

J. Jassem, J. Limon, B. Wysocka, 1999, Gynecologic oncology.

Cancer predisposing BARD1 mutations affect exon skipping and are associated with overexpression of specific BARD1 isoforms.

I. Irminger-Finger, G. Laurent, P. Kozłowski, 2015, Oncology reports.

Analysis of large mutations in BARD1 in patients with breast and/or ovarian cancer: the Polish population as an example

I. Irminger-Finger, M. Stukan, P. Kozłowski, 2015, Scientific Reports.

Cancer predisposing BARD 1 mutations affect exon skipping and are associated with overexpression of specific BARD 1 isoforms

I. Irminger-Finger, G. Laurent, P. Kozłowski, 2015 .

HER2 Amplification Has no Prognostic Value in Sporadic and Hereditary Ovarian Tumours

M. Stukan, J. Limon, M. Ratajska, 2006, Hereditary cancer in clinical practice.

Trisomy 12 and 4 in a thecoma of the ovary.

K. Mrózek, J. Limon, J. Emerich, 1992, Gynecologic oncology.

Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma

P. Devilee, J. Jassem, C. Cornelisse, 2005, Cancer.

Cancer predisposing BARD1 mutations in breast-ovarian cancer families

M. Stukan, J. Limon, M. Matusiak, 2012, Hereditary Cancer in Clinical Practice.

P21WAF1, P27KIP1, TP53 and C-MYC analysis in 204 ovarian carcinomas treated with platinum-based regimens.

M. Jedryka, A. Płużańska, J. Kupryjańczyk, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen

M. Jedryka, A. Płużańska, J. Kupryjańczyk, 2003, British Journal of Cancer.

[A rare case of non-Hodgkin's lymphoma of the uterine cervix].

P. Mielcarek, M. Liro, J. Emerich, 2001, Ginekologia polska.

CLINICAL ANALYSIS OF PATIENTS WITH KRUKENBERG TUMOR OF THE OVARY

M. Stukan, J. Emerich, J. Dębniak, 2004, International Journal of Gynecologic Cancer.

ovarian cancer in a family with coexistence of germline nf1 and brca1 mutations case report

J. Limon, Magdalena Koczkowska, Alina Kuźniacka, 2018 .

Spectrum and Prevalence of Pathogenic Variants in Ovarian Cancer Susceptibility Genes in a Group of 333 Patients

M. Stukan, P. Kozłowski, J. Limon, 2018, Cancers.